Luput Cristian 4

What Happened Cristian Luput, a director of MAIA Biotechnology, received a grant of 27,610 derivative securities (stock options) on June 30, 2026. The Form 4 records the acquisition at $0.00 (grant/award), indicating an option award rather than a cash purchase or sale. The filing does not state an aggregate dollar value or the option exercise price.

Key Details

• Transaction date: 2026-06-30; Form 4 filed 2026-07-02 (timely filing).
• Transaction type/code: Award/Grant (derivative) — 27,610 options acquired at $0.00.
• Vesting/exercisability: Per the filing footnote, the options vest 100% on the grant date and are exercisable beginning on that date.
• Shares owned after transaction: Not specified in the provided filing.
• Notable footnote: F1 confirms immediate vesting and exercisability under MAIA’s 2021 Equity Incentive Plan.
• No indication in this filing of an immediate exercise or sale of shares.

Context This was an option grant (compensation-style award), not an open-market purchase or sale. Although the options are exercisable immediately, exercising would require paying the exercise price (not disclosed here) and potentially trigger tax or withholding events. Option grants are common for directors and do not by themselves signal a purchase-driven bullish bet unless the insider later exercises and holds shares.